HER2+ Breast Cancer | Specialty

Optimal Timing for Neratinib

February 2nd 2018

Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?

February 2nd 2018

Factors Influencing Adjuvant Therapy Use for HER2+ Breast Cancer

February 2nd 2018

The ExteNET Trial

February 2nd 2018

The APHINITY Trial

February 2nd 2018

Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

February 2nd 2018

Tucatinib Combo Explored in HER2-Positive Breast Cancer

February 1st 2018

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Trastuzumab Biosimilar Demonstrates Equivalence in HER2+ Breast Cancer

January 31st 2018

The trastuzumab (Herceptin) biosimilar SB3 induced a rate of breast pathologic complete response similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.

Dr. Isaacs Discusses the Role of Neratinib in HER2+ Breast Cancer

January 26th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the role of neratinib (Nerlynx) in the treatment landscape of HER2-positive breast cancer.

Dr. Ellis on Immunotherapy in HER2+ Breast Cancer

January 23rd 2018

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients

January 17th 2018

Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.

Dr. Borgen Discusses Trials in Neoadjuvant HER2+ Breast Cancer

January 16th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses clinical trials in neoadjuvant HER2 breast cancer.

Novel Treatments Emerging in HER2+ Breast Cancer Pipeline

January 8th 2018

Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.

Dr. Tolaney on the Evolution of Adjuvant Treatment for HER2+ Breast Cancer

January 3rd 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

Pertuzumab and Other Agents Continue Progress in HER2+ Breast Cancer

January 2nd 2018

Adam M. Brufsky, MD, PhD, discusses the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.

Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer

December 29th 2017

The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.

Long-Term Data Published for Neratinib in HER2+ Breast Cancer

December 29th 2017

Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.

Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer

December 28th 2017

Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.

Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

December 21st 2017

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 21st 2017

The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.